Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research report released on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.

Cellectis Stock Performance

NASDAQ CLLS opened at $1.75 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. The stock’s 50 day simple moving average is $2.06 and its 200-day simple moving average is $2.27. The company has a market cap of $97.27 million, a PE ratio of -1.35 and a beta of 3.10. Cellectis has a 1-year low of $1.70 and a 1-year high of $3.77.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 78.25%. The firm had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. During the same quarter in the previous year, the business posted ($0.31) EPS. As a group, equities research analysts anticipate that Cellectis will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CLLS. Long Focus Capital Management LLC grew its position in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after buying an additional 12,467 shares during the last quarter. First Affirmative Financial Network purchased a new stake in Cellectis in the 3rd quarter valued at $45,000. Finally, XTX Topco Ltd acquired a new stake in shares of Cellectis in the 2nd quarter worth $29,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.